Psychedelics are going mainstream. Not only is the US FDA supportive of research, dozens of medical studies are proving such treatments could be helpful, including Johns Hopkins Medicine and New York University.
Psilocybin has been found to help treat mental health issues, such as depression, anxiety, obsessive-compulsive disorder, PTSD, and possibly even eating disorders.LSD may be able to help patients with anxiety disorders and other medical issues. MDMA-assisted therapy could help treat eating disorders, including anorexia and binge eating. All have been major catalysts for related companies.
Now, a New Psychedelic ETF Could Give the Industry a Boost
Another key catalyst could be the upcoming Horizons Psychedelic Stock Index (ETF) that is expected to commence trading Jan. 27, 2021 under ticker PSYK on the NEO Exchange. Some of the companies included in the ETF are Compass Pathways, MindMed, Field Trip Health, Revive Therapeutics, Cybin, and Mind Cure Health.